Sorafenib therapy is associated with improved outcomes for FLT3-ITD AML relapsing after allo-HSCT
Internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations have been reported in approximately 25% of patients with acute myeloid leukemia (AML) [1]. In contrast to patients with FLT3-ITD wild-type, AML with FLT3-ITD mutations have inferior survival, primarily due to a shorter remission duration and higher relapse rate [2]. Although allogeneic hematopoietic stem cell transplantation (allo-HSCT) improves the outcomes for AML with FLT3-ITD, they are still associated with a higher relapse rate post-transplant compared with patients who are FLT3-ITD wild-type [3 –5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 19, 2019 Category: Hematology Authors: Li Xuan, Yu Wang, Jia Chen, Erlie Jiang, Li Gao, Bingyi Wu, Lan Deng, Xinquan Liang, Fen Huang, Zhiping Fan, Xiaowen Tang, Jing Sun, Xi Zhang, Mingzhe Han, Depei Wu, Xiaojun Huang, Qifa Liu Source Type: research

Severe Herpes Zoster Requiring Intravenous Antiviral Treatment in Allogeneic Hematopoietic-cell Transplantation Recipients on Standard Acyclovir Prophylaxis
Allogeneic hematopoietic cell transplant (HCT) recipients are at increased risk for varicella zoster virus reactivation and associated complications. The incidence, timing, and risk factors for severe herpes zoster (HZ) are not well described in the era of acyclovir (ACV) prophylaxis. We performed a retrospective cohort study of all patients who underwent first allogeneic HCT from October 2006 to December 2015 at our institution. Patients were followed until December 2017 for the development of severe HZ, defined as requiring administration of intravenous antiviral medication. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 17, 2019 Category: Hematology Authors: Emily Baumrin, Matthew P. Cheng, Sanjat Kanjilal, Vincent T. Ho, Nicolas C. Issa, Lindsey R. Baden Source Type: research

Have we achieved a Goldilocks grade of GVHD?
Post-transplantation cyclophosphamide (PTCy) has enabled near-universal donor access and expanded the pool of patients eligible for a haploidentical allogeneic transplant. While often used in combination with a calcineurin inhibitor (CNI), it can be used as sole GVHD prophylaxis in HLA-identical transplantation following myeloablative conditioning. Previous approaches using CNI-free approaches have included ex vivo T cell depletion (TCD) using immunomagnetic selection of CD34+ cells and in vivo TCD using antithymocyte globulin (ATG) [1,2]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Sumithira Vasu, Samantha Jaglowski Source Type: research

Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation
The outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) are poor. A retrospective analysis of adults with ALL who relapsed after first alloHSCT and received salvage therapies, including a second HSCT, donor lymphocyte infusion with or without prior chemotherapy, radiation therapy, cytoreductive chemotherapy, mild chemotherapy, or palliative care, showed 1- and 2-year overall survival rates of 17% and 10%, respectively [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Anthony S. Stein, Hagop Kantarjian, Nicola G ökbuget, Ralf Bargou, Mark R. Litzow, Alessandro Rambaldi, Josep-Maria Ribera, Alicia Zhang, Zachary Zimmerman, Gerhard Zugmaier, Max S. Topp Source Type: research

The challenge to predict mobilized peripheral blood stem cells on the fourth day of G-CSF treatment in healthy donors: the predictive value of basal CD34+ cell and platelet counts
In recent years, the number of allogeneic (Allo) stem cell transplantations (SCTs) has progressively increased worldwide [1,2]. Mobilized peripheral blood (PB) stem cells (PBSCs), compared with bone marrow grafts, have a higher stem cell content, lead to faster engraftment [3,4], and are more convenient for collection and, as a consequence, the use of PBSCs grafts have significantly increased. Initially, there were concerns about mobilization in the allogeneic setting due to normal donor toxicity [5,6] and the risk for graft-versus-host disease in the recipient [7], but studies have demonstrated G-CSFs to be well-tolerated...
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Massimo Martino, Mercedes Gori, Tiziana Moscato, Virginia Naso, Anna Ferreri, Fabio Provenzano, Barbara Loteta, Maria Cristina Sanguedolce, Giuseppe Console, Antonia Dattola, Giulia Pucci, Massimo Gentile, Antonella Morabito, Anna Grazia Recchia, Giovanni Source Type: research

Worldwide Network for Blood and Marrow Transplantation (WBMT) recommendations for establishing a hematopoietic stem cell transplantation program in countries with limited resources (Part II): clinical, technical and socio-economic considerations
The development of hematopoietic stem cell transplantation (HSCT) programs can face significant challenges in most developing countries because such endeavors must compete with other government health care priorities, including the delivery of basic services. While this is may be a limiting factor, these countries should prioritize development of the needed expertise to offer state of the art treatments including transplantation, by providing financial, technological, legal, ethical and other needed support. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: M. Aljurf, D. Weisdorf, SK. Hashmi, A. Nassar, E. Gluckman, M. Mohty, D. Rizzo, M. Pasquini, M. Hamadani, W. Saber, P. Hari, M. Kharfan-Dabaja, N. Majhail, U. Gerges, A. Ali Hamidieh, F. Hussain, A. Elhaddad, HK. Mahmoud, A. Tbakhi, TB. Othman, RM. Hamlad Source Type: research

Levofloxacin versus cefpodoxime for antibacterial prophylaxis in allogeneic stem cell transplantation
Allogeneic hematopoietic stem cell transplant (HSCT) patients are at considerable risk for infection due to prolonged neutropenia caused by myeloablative and immunosuppressive conditioning regimens. Both the National Comprehensive Cancer Network (NCCN) and the American Society of Blood and Marrow Transplantation (ASBMT) recommend that prophylaxis with antibiotics should be considered in patients at high risk for neutropenia, including those receiving a stem cell transplant [1,2]. According to guidelines from the American Society of Clinical Oncology (ASCO), Infectious Diseases Society of America (IDSA), and ASBMT, antibact...
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Vi P. Doan, Jason C. Yeh, Alison M. Gulbis, Samuel L. Aitken, Ella Ariza-Heredia, Sairah Ahmed Source Type: research

Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults
Prognosis of pediatric acute lymphoblastic leukemia (ALL) has dramatically improved and recent studies report excellent results [1]. Although the survival rate now approaches 90% for childhood ALL overall, adolescents and young adults (AYAs) still have a poor prognosis [2,3]. ALL in AYA patients commonly show certain unfavorable biological and molecular genetic features compared to younger children, including lower frequency of ETV6-RUNX1 and high-hyperdiploidy, and higher frequency of BCR-ABL1, DUX4-translocation, and positive minimal residual disease after induction therapy [2 –4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Mayumi Hangai, Kevin Y. Urayama, Junji Tanaka, Koji Kato, Satoshi Nishiwaki, Katsuyoshi Koh, Maiko Noguchi, Keisuke Kato, Nao Yoshida, Maho Sato, Hiroaki Goto, Yuki Yuza, Yoshiko Hashii, Yoshiko Atsuta, Shuichi Mizuta, Motohiro Kato Source Type: research

Incidence and outcomes of bacterial bloodstream infections during acute graft-versus-host disease involving the gastrointestinal tract following hematopoietic-cell transplant
Bloodstream infections (BSIs) are among the most common infectious complications of allogeneic hematopoietic-cell transplant (HCT) [1]. Most BSIs occur in the early ( (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Jenna Petersen, Christian Lindner, Morgan Hakki Source Type: research

Population Pharmacokinetics of Clofarabine as Part of Pre-Transplant Conditioning in Pediatric Subjects Prior to Hematopoietic Cell Transplantation (HCT)
Although major advancements have been made in recent years through improvements in supportive care, high rates of engraftment failure and disease relapse remain prominent clinical problems in allogeneic hematopoietic cell transplantation (HCT). Historically, fludarabine has been included in most reduced intensity allogeneic HCT conditioning regimens in combination with an alkylating agent, such as busulfan (BuFlu). More recently, combining clofarabine with BuFlu has been evaluated in an attempt to improve efficacy in children undergoing alloHCT for the treatment of leukemia and various non-malignant disorders [1]. (Source:...
Source: Biology of Blood and Marrow Transplantation - April 16, 2019 Category: Hematology Authors: Hechuan Wang, Aksana K. Jones, Christopher C Dvorak, Liusheng Huang, Paul Orchard, Vijay Ivaturi, Janel Long-Boyle Source Type: research

Outcomes of Related and Unrelated Donor Searches Among Patients with Primary Immunodeficiency Diseases Referred for Allogeneic Hematopoietic Cell Transplantation
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative therapy for patients with inherited diseases of the immune and hematopoietic system, globally referred to as primary immunodeficiencies (PIDs). Many of the more common and long-recognized PIDs have an autosomal recessive (AR) or X-linked (XL) mode of inheritance, such as Wiskott-Aldrich syndrome, chronic granulomatous disease (CGD), and severe combined immunodeficiency (SCID), wherein patients are typically diagnosed and treated with HCT or gene therapy at a very early age. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 12, 2019 Category: Hematology Authors: Mary Joseph Acevedo, Jennifer S. Wilder, Sharon Adams, Joie Davis, Corin Kelly, Dianne Hilligoss, Ellen Carroll, Bazetta Blacklock-Schuver, Kristen Cole, Elizabeth M. Kang, Amy P. Hsu, Christopher G. Kanakry, Dimana Dimitrova MD, Jennifer A. Kanakry MD Source Type: research

Health Care Utilization is High in Adult Patients Relapsing After Allogeneic Hematopoietic Cell Transplantation
Disease relapse is the leading cause of death for patients with acute leukemia (AL) and myelodyspastic syndrome (MDS) who undergo allogeneic hematopoietic cell transplantation (HCT). Relapse post-HCT is associated with poor prognosis; however, the inpatient health care utilization of this population is unknown. Here we describe survival, intensity of health care utilization, and characteristics associated with high resource utilization at the end-of-life (EOL).Adult patients with AL/MDS who underwent HCT at a large regional referral center with subsequent relapse between 2005 and 2015 were included in this retrospective st...
Source: Biology of Blood and Marrow Transplantation - April 5, 2019 Category: Hematology Authors: Jessica A. Langston, Vandana Sundaram, Vyjeyanthi S. Periyakoil, Lori Muffly Source Type: research

A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Multiple myeloma (MM) is the second most common adult hematologic malignancy in the western hemisphere, with an estimated 30,770 new cases and 12,770 expected deaths in 2018 [1]. While it remains an incurable cancer, survival outcomes of patients with MM have continued to increase particularly with the use of novel therapies, such as proteasome inhibitors (PI) and immunomodulatory drugs (IMID) [2], as well as treatment paradigms including upfront high-dose therapy/ autologous hematopoietic cell transplantation (HDT/AHCT) and post-transplant maintenance treatment [3]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 5, 2019 Category: Hematology Authors: Anita D'Souza, Parameswaran Hari, Marcelo Pasquini, Thomas Braun, Bryon Johnson, Steven Lundy, Daniel Couriel, Mehdi Hamadani, John Magenau, Binod Dhakal, Nirav N. Shah, Mary Riwes, Brian Parkin, Pavan Reddy, Attaphol Pawarode Source Type: research

Safety and seropositivity after live attenuated vaccine in adult patients receiving hematopoietic stem cell transplantation
Several guidelines for vaccination of the immunocompromised host recommend that recipients of autologous and allogeneic hematopoietic stem cell transplantation (HSCT) receive vaccination against vaccine-preventable diseases (VPDs) [1-4]. Long-term survivors in HSCT recipients can eventually develop life-threatening infectious complications due to the loss of their immunity, although the hematological diseases remain cured. Therefore, it becomes more important to manage infections adequately, especially if they can be prevented in advance. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 5, 2019 Category: Hematology Authors: Takatoshi Aoki, Tomohiko Kamimura, Shuro Yoshida, Yasuo Mori, Masanori Kadowaki, Kentaro Kohno, Daisuke Ishihara, Shingo Urata, Takeshi Sugio, Kenjiro Kamezaki, Koji Kato, Yoshikiyo Ito, Tetsuya Eto, Koichi Akashi, Toshihiro Miyamoto Source Type: research

Gastrointestinal Microbiome and Mycobiome changes during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study
Hematopoietic cell transplantation (HCT) is frequently associated with severe toxicities, including graft-vs-host disease (GVHD), gastrointestinal mucositis, and opportunistic infections. Since the 1970s the microbiome, specifically intestinal microbiota, and their metabolites have been recognized as key mediators of allogeneic HCT outcomes including GVHD and overall survival (OS) [1-10]. The microbiome has been shown to influence post-transplant hematologic reconstitution, including that of dendritic cells, neutrophils, B-cell and T-cell subsets, and natural killer cells [11-19]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 5, 2019 Category: Hematology Authors: Najla El Jurdi, Ali Filali-Mouhim, Iman Salem, Mauricio Retuerto, Nina Margaret Dambrosio, Linda Baer, Hillard M. Lazarus, Paolo Caimi, Brenda Cooper, Benjamin Tomlinson, Leland Metheny, Ehsan Malek, Folashade Otegbeye, Rafick-Pierre Sekaly, Mahmoud Ghann Source Type: research

Corrigendum to ‘Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus host disease guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed Acute Leukemia’ [Biology of Blood and Marrow Transplantation 23/8 (2017) 1311-1319]
The authors regret that in the above-mentioned article, the description “…4-color flow cytometry (FCM)” (Lines 30-31, right column, Page 1312) was incorrectly. The correct description should be “….8-color flow cytometry (FCM)”. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 4, 2019 Category: Hematology Authors: Chen-Hua Yan, Qi-fa Liu, De-pei Wu, Xi Zhang, Lan-Ping Xu, Xiao-hui Zhang, Yu Wang, He Huang, Hai Bai, Fen Huang, Xiao Ma, Xiao-Jun Huang Tags: Corrigendum Source Type: research

Corrigendum to ‘Interferon α: A potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation’ [Biology of Blood and Marrow Transplantation 21/11 (2015) 1939-1947]
The authors regret that in the above-mentioned article, the description “LAIPs were detected by 4-color flow cytometry (FACSCalibur, Becton and Dickinson, San Jose, CA).” (Lines 29-31, right column, Page 1940) was incorrectly. The correct dscription should be “LAIPs were detected by 8-color flow cytometry (FCM) (FACSCato II; BD Biosciences, San Jose, CA).” (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 4, 2019 Category: Hematology Authors: Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang Tags: Corrigendum Source Type: research

Corrigendum to ‘Interferon-α is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: results of a registry study’ [Biology of Blood and Marrow Transplantation 23/8 (2017) 1303-1310]
The authors regret in the above-mentioned article, the description “LAIPs were detected by 4-color flow cytometry (FACSCalibur, Becton and Dickinson, San Jose, CA).” (Lines 18-19, right column, Page 1304) was incorrectly. The correct dscription should be “LAIPs were detected by 8-color flow cytometry (FCM) (FACSCato II; BD Biosciences, San Jose, CA).” (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 3, 2019 Category: Hematology Authors: Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang Tags: Corrigendum Source Type: research

Donor-derived CIK Cell Infusion as Consolidation after Non-myeloablative Allogeneic Transplant for Myeloid Neoplasms
Reduced intensity (RIC) and non-myeloablative (NMA) conditioning regimens are often utilized for patients with myeloid neoplasms of older age or with concurrent comorbid conditions undergoing allogeneic hematopoietic cell transplant (allo-HCT) due to high incidence of treatment related toxicity with myeloablative conditioning. In an analysis of 61 patients with myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), or therapy-related myeloid neoplasms (t-MN) undergoing NMA conditioning combining total lymphoid irradiation (TLI) with anti-thymocyte globulin (ATG) [1 –3], 3-year overall survival (OS) was 4...
Source: Biology of Blood and Marrow Transplantation - April 2, 2019 Category: Hematology Authors: Rupa Narayan, Jonathan E. Benjamin, Omid Shah, Lu Tian, Keri Tate, Randall Armstrong, Bryan Xie, Robert Lowsky, Ginna Laport, Robert S. Negrin, Everett H. Meyer Source Type: research

Unrelated donor peripheral blood stem cell transplantation for patients with β-thalassaemia major based on a novel conditioning regimen
Currently, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only curative treatment for β-thalassemia major (β-TM) [1]. The widest clinical experience of allo-HSCT in TM has been obtained using grafts harvested from a human leukocyte antigen (HLA)-well-matched sibling donor (SD) [2,3]. However, only approximately one in three of patients has a matched sibling donor (MSD) within the f amily [4], alternative transplantation strategies that using allografts from alternative donors are needed. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 2, 2019 Category: Hematology Authors: Lan Sun, Na Wang, Yi Chen, Liyuan Tang, Chongyun Xing, Nina Lu, Yifen Shi, Yongyong Ma, Fengyang Lin, Kang Yu, Jianhua Feng Source Type: research

Masthead (Purpose and Scope)
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2019 Category: Hematology Source Type: research

Editorial Board
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2019 Category: Hematology Source Type: research

Officers and Directors of ASBMT
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2019 Category: Hematology Source Type: research

Table of Contents
(Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - April 1, 2019 Category: Hematology Source Type: research

ASBMT Notes
The American Society for Blood and Marrow Transplantation (ASBMT), a professional society dedicated to advancing the science and clinical care for patients who require blood and marrow transplants, today announced it has changed its name to the American Society for Transplantation and Cellular Therapy (ASTCT) in recognition of the rapid shift toward cellular therapies in this field of medicine. TheASTCT name will better reflect the organization's commitment to serving as the professionalhome and community for healthcare providers, researchers, and other professionals who are dedicated to cures involving blood and marrow tr...
Source: Biology of Blood and Marrow Transplantation - April 1, 2019 Category: Hematology Tags: ASBMT Notes Source Type: research

Influence of Donor and Recipient Gender on Telomere Maintenance after Umbilical Cord Blood Cell Transplantation: A Study by the Gruppo Italiano Trapianto Di Midollo Osseo
Telomeres are noncoding long-tandem-repeated sequences at the ends of chromosomes that prevent chromosomal fusions, accumulation of DNA damage, and degradation of coding DNA [1,2]. Telomere maintenance is crucial for genomic stability in eukaryotic cells, because telomere shortening leads to accumulation of DNA damage and replicative senescence or cell death [2]. Telomere shortening is prevented by human telomerase (hTERT), an enzyme able to add nucleotides pairs de novo, restoring telomere sequences [3 –7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 29, 2019 Category: Hematology Authors: E. Derenzini, A. Risso, M. Ruella, T. Spatola, G. Milone, P. Pioltelli, A.P. Iori, S. Santarone, A. Bosi, A. Rambaldi, A.P. Bacigalupo, W. Arcese, Corrado Tarella Tags: Cord Blood Source Type: research

Influence of donor and recipient gender on telomere maintenance following umbilical cord blood cell transplantation: a study by gitmo (gruppo italiano trapianto di midollo osseo)
Telomeres are non-coding long tandem repeated sequences at the ends of chromosomes, which prevent chromosomal fusions, accumulation of DNA damage and degradation of coding DNA [1,2]. Telomere maintenance is crucial for genomic stability in eucariotic cells, as telomere shortening leads to accumulation of DNA damage and replicative senescence or cell death [2]. Telomere shortening is prevented by human telomerase (hTERT) an enzyme able to add nucleotides pairs de novo, restoring telomere sequences [3 –7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 29, 2019 Category: Hematology Authors: E. Derenzini, A. Risso, M. Ruella, T. Spatola, G. Milone, P. Pioltelli, A.P. Iori, S. Santarone, A. Bosi, A. Rambaldi, A.P. Bacigalupo, W. Arcese, C. Tarella Source Type: research

Comparison of Dynamic International Prognostic Scoring System and MYelofibrosis SECondary to PV and ET Prognostic Model for Prediction of Outcome in Polycythemia Vera and Essential Thrombocythemia Myelofibrosis after Allogeneic Stem Cell Transplantation
In the last decade 3 clinical-derived prognostic models have been developed in patients with primary myelofibrosis [1-3]. Prognostication in myeloproliferative neoplasms, however, is moving toward integrated clinical-molecular models [4,5]. Therefore, more recently another prognostic system has been developed and validated by the MYSEC project (MYelofibrosis SECondary to PV and ET) specifically for myelofibrosis evolved from polycythemia vera (post-PV MF) and essential thrombocythemia (post-ET MF) [6,7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 28, 2019 Category: Hematology Authors: Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Christine Wolschke, Renate Arnold, Lothar Kanz, Grant McQuaker, Tony Marchand, Gerard Soci é, Jean Henri Bourhis, Mohamad Mohty, Jan J Cornelissen, Patrice Chevallier, Paolo Bernasco Source Type: research

Pretreatment CD34+/CD38 – Cell Burden as Prognostic Factor in Myelodysplastic Syndrome Patients Receiving Allogeneic Stem Cell Transplantation
Myelodysplastic syndromes (MDS) and MDS/myeloproliferative neoplasm (MPN) are heterogeneous clonal hematopoietic disorders resulting in inefficient hematopoiesis and a variable progression risk to secondary acute myeloid leukemia (sAML) [1-3]. At diagnosis, the International Prognostic Scoring System (IPSS) [1] and the revised IPSS (IPSS-R) [2] are commonly used to estimate disease aggressiveness for subsequent therapeutic decision-making. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for MDS patients and is of particular interest in high-risk disease [4]. (Source: Bio...
Source: Biology of Blood and Marrow Transplantation - March 28, 2019 Category: Hematology Authors: Madlen Jentzsch, Ulrike Geus, Juliane Grimm, Vladan Vucinic, Wolfram P önisch, Georg-Nikolaus Franke, Gerhard Behre, Dietger Niederwieser, Sebastian Schwind Source Type: research

The pre-treatment CD34+/CD38- cell burden as prognostic factor in MDS patients receiving allogeneic stem cell transplantation
Myelodysplastic Syndromes (MDS) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are heterogeneous clonal hematopoietic disorders resulting in inefficient hematopoiesis and a variable progression risk to secondary acute myeloid leukemia (AML).1-3 At diagnosis, the international prognostic scoring system (IPSS)1 and the revised international prognostic scoring system (IPSS-R)2 are commonly used to estimate disease aggressiveness for subsequent therapeutic decision making. Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only curative treatment option for MDS patients and is of particular intere...
Source: Biology of Blood and Marrow Transplantation - March 28, 2019 Category: Hematology Authors: Dr. Madlen Jentzsch, Ulrike Geus, Juliane Grimm, Dr. Vladan Vucinic, Dr. Wolfram P önisch, Dr. Georg-Nikolaus Franke, Prof. Dr. Gerhard Behre, Prof. Dr. Dietger Niederwieser, PD Dr. Sebastian Schwind Source Type: research

Comparison of DIPSS and MYSEC-PM for prediction of outcome in post-PV and ET myelofibrosis after allogeneic stem-cell transplantation
In the last decade, three clinical-derived prognostic models have been developed in patients with primary myelofibrosis [1 –3]. Prognostication in myeloproliferative neoplasms, however, is moving towards integrated clinical-molecular models [4,5]. Therefore, more recently, another prognostic system has been developed and validated by the MYSEC project (MYelofibrosis SECondary to PV and ET) specifically for myelofibros is evolved from polycythemia vera (post-PV MF) and essential thrombocythemia (post-ET MF) [6,7]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 28, 2019 Category: Hematology Authors: Nico Gagelmann, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Christine Wolschke, Renate Arnold, Lothar Kanz, Grant McQuaker, Tony Marchand, Gerard Soci é, Jean Henri Bourhis, Mohamad Mohty, Jan J Cornelissen, Patrice Chevallier, Paolo Bernasco Source Type: research

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies
Haploidentical stem cell transplantations using high-dose post-transplant cyclophosphamide (PTCY) are increasingly used in patients lacking suitable matched donors [1]. The Baltimore reduced-intensity conditioning (RIC) regimen, combining fludarabine, low doses of cyclophosphamide and total body irradiation, followed by PCTY, has become a standard of care in this setting in some institutions [2]. Recently we reported the encouraging results of a “Clo-Baltimore” RIC regimen for myeloid malignancies where fludarabine was replaced by clofarabine and bone marrow by peripheral blood stem cells (PBSCs) as the source ...
Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Louise Bouard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Alix Duquenne, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Yannick Le Bris, Anne Lok, Antoine Bonnet, Steven Le Gouill, Philippe Source Type: research

Pharmacological considerations in antithymocyte globulin exposure calculation
With much interest, we read the paper published by Jamani et al in BBMT1. The authors describe the pharmacokinetics of anti-thymocyte globulin (ATG), and investigate the relationship between ATG exposure and outcome. Most notable are the findings that low area under the curve (AUC) of ATG before graft infusion led to worse chronic GvHD and relapse-free survival, while low AUC after graft infusion was associated with higher risk on acute GvHD incidence. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Rick Admiraal, Moniek A. de Witte, Alwin Huitema, Stefan Nierkens Tags: Letter-to-the-Editor Source Type: research

Influence of donor type (sibling vs matched-unrelated donor vs haplo-identical donor) on outcomes after clofarabine-based reduced-intensity conditioning allograft for myeloid malignancies.
Haploidentical stem cell transplantations using high-dose post-transplant cyclophosphamide (PTCY) are increasingly used in patients lacking suitable matched donors [1]. The Baltimore reduced-intensity conditioning (RIC) regimen, combining fludarabine, low-doses of cyclophosphamide and total body irradiation (TBI), followed by PCTY, has become a standard of care in this setting in some institutions [2]. Recently, we have reported the encouraging results of a “Clo-Baltimore” RIC regimen for myeloid malignancies where fludarabine was replaced by clofarabine and bone marrow by peripheral blood stem cells (PBSC) as ...
Source: Biology of Blood and Marrow Transplantation - March 27, 2019 Category: Hematology Authors: Louise Bouard, Thierry Guillaume, Pierre Peterlin, Alice Garnier, Amandine Le Bourgeois, Alix Duquenne, Beatrice Mahe, Viviane Dubruille, Nicolas Blin, Cyrille Touzeau, Thomas Gastinne, Yannick Le Bris, Anne Lok, Antoine Bonnet, Steven Le Gouill, Philippe Source Type: research

Comparable outcomes of first-line hematopoietic stem cell transplantation from unrelated and matched sibling donors in adult patients with aplastic anemia: A retrospective single-centre study
Aplastic anemia (AA), characterized by peripheral pancytopenia, bone marrow (BM) hypocellularity, and hematopoietic stem cell niche number impairment, is a potentially fatal disorder for which immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) are the principal interventions.1-3 According to the treatment guidelines, upfront HSCT from an HLA-matched sibling donor (MSD) is recommended for severe AA (SAA) patients younger than 35 years.4 If no MSD is available, horse anti-thymocyte globulin (ATG)-based IST is indicated, and allo-HSCT from an unrelated donor (URD) is considered ...
Source: Biology of Blood and Marrow Transplantation - March 26, 2019 Category: Hematology Authors: Yuping Zhang, Liangliang Wu, Wenjian Mo, Ming Zhou, Yumiao Li, Xiaowei Chen, Caixia Wang, Shiyi Pan, Shilin Xu, Wei Zhou, Ruiqing Zhou, Shunqing Wang Source Type: research

Risks and outcomes of allogeneic hematopoietic stem cell transplantation for hematologic malignancies in patients with Human immunodeficiency virus Infection
The worldwide prevalence of Human Immunodeficiency Virus (HIV) is around 37 million and antiretroviral therapy (ART) has considerably improved survival in HIV infected patients with dramatic declines in morbidity and mortality since its availability1-3. Despite these improvements, about one million HIV related deaths occur annually. Persons living with HIV (PLHIV) are at a higher risk of developing both hematologic and solid organ malignancies as compared to the general population despite the use of ART4. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 26, 2019 Category: Hematology Authors: Shukaib Arslan, Mark R. Litzow, Nathan W. Cummins, Stacey A. Rizza, Andrew D. Badley, Willis Navarro, Shahrukh K. Hashmi Source Type: research

Reply
We thank Ms Brown and Dr Gutierrez for their comments regarding our recent publication of the ASBMT CRS and ICANS Consensus Grading [1], and we agree that there are significant clinical differences between patients requiring a low dose versus a high dose of 1 vasopressor. This was an active area of discussion among the larger group. However, we expressly stated that the Consensus Grading is not a treatment guideline, and no inference in such regard should be made. Rather, grading of CRS is entirely dependent on the interventions the patient requires and is not a meant as a tool to suggest one intervention or another. (Sour...
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Daniel W. Lee, Elena Mead, Bianca D. Santomasso, Cameron J. Turtle, Stephan A. Grupp, Sattva S. Neelapu Source Type: research

Reduced Plasma Amino Acid Levels During Allogeneic Hematopoietic Stem Cell Transplantation Are Associated with Systemic Inflammation and Treatment-Related Complications
Although allogeneic myeloablative hematopoietic stem cell transplantation (HSCT) has improved survival in patients with severe hematologic diseases, this treatment is challenged by severe adverse events due to immunosuppression, acute graft-versus-host disease (aGVHD), and direct cytotoxicity of the conditioning regimen [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Sarah Weischendorff, Katrine Kielsen, Maria Nederby, Lotte Svendsen, Douglas Burrin, Carsten Heilmann, Marianne Ifversen, Henrik Sengel øv, Christian Mølgaard, Klaus Müller Source Type: research

A phase I/II, open-label, prospective, multicenter study to evaluate the efficacy and safety of lower doses of bortezomib plus busulfan and melphalan as a conditioning regimen in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation: The KMM103 study
Single-agent, high-dose melphalan is a standard conditioning option in patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT).[1,2] Despite the advantages of ASCT using melphalan at a high dose of 200 mg/m2 over the non-transplant approach,[3] the results of ASCT in MM are still unsatisfactory because this approach is not curative, and inevitable relapse remains the primary cause of death. Few alternatives for ASCT have been explored to improve the antimyeloma activity of classic conditioning with high-dose melphalan. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Sung-Soo Park, Kihyun Kim, Seok-Jin Kim, Jae Hoon Lee, Sung Soo Yoon, Yeung Chul Mun, Je-Jung Lee, Hyeon-Seok Eom, Jin Seok Kim, Chang-Ki Min, Korean Multiple Myeloma Working Party Source Type: research

Comparing a neutropenic diet to a food safety-based diet in pediatric patients undergoing hematopoietic stem cell transplantation
Nutrition during hematopoietic stem cell transplant (HSCT) has evolved over the past 50 years. In the 1960 ’s, HSCT recipients were placed in a total protective environment, and all items, including clothes and linens were sterilized prior to being taken into the bone marrow transplant unit. All food was sterilized, and HSCT recipient gastrointestinal tracts were “cleansed” with castor oil and anti biotics [1-3]. The diet order for a patient receiving HSCT was known as the neutropenic diet (also known as the immune compromised diet, low bacteria diet, low microbial diet, or sterile diet) [1,4-6]. (Source:...
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Cynthia Taggart, Nicole Neumann, Priscila Badia Alonso, Adam Lane, Abigail Pate, Audrey Stegman, Ava Stendahl, Stella M. Davies, Christopher E. Dandoy, Michael Grimley Source Type: research

Reduced plasma amino acid levels during allogeneic haematopoietic stem cell transplantation are associated with systemic inflammation and treatment-related complications
Although allogeneic myeloablative haematopoietic stem cell transplantation (HSCT) has improved survival in patients with severe haematological diseases, the treatment is challenged by severe adverse events due to immunosuppression, acute graft-versus-host disease (aGvHD), and direct cytotoxicity of the conditioning regimen [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Sarah Weischendorff, Katrine Kielsen, Maria Nederby, Lotte Svendsen, Douglas Burrin, Carsten Heilmann, Marianne Ifversen, Henrik Sengel øv, Christian Mølgaard, Klaus Müller Source Type: research

Authors ’ Response to the Letter-to-the-Editor by Brown ART and Gutierrez C.
The authors thank Ms. Brown and Dr. Gutierrez for their comments regarding our recent publication of the ASBMT CRS and ICANS consensus grading [1] (The Consensus Grading) and we agree with them that there are significant clinical differences between patients requiring low- versus high-dose of one vasopressor. This was an active area of discussion amongst the larger group. However, we expressly stated that The Consensus Grading is not a treatment guideline and no inference in such regard should be made. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 22, 2019 Category: Hematology Authors: Daniel W. Lee, Elena Mead, Bianca D. Santomasso, Cameron J. Turtle, Stephan A. Grupp, Sattva S. Neelapu Source Type: research

Protecting the Selfless: Toward More Comprehensive Care for Pediatric Related Stem Cell Donors
In this issue of the journal Pulsipher et al. [1] describe findings from the multi-institutional National Heart, Lung, and Blood Institute –funded RDSafe study, a prospective North American trial evaluating hematopoietic stem cell (HSC) donors of all ages predonation through 1 year after the collection procedure. After an earlier report from the study showed that many pediatric donors experience decreased health-related quality of li fe after donation [2], a more detailed assessment of pain, toxicities, and serious adverse events was undertaken in 294 donors younger than age 18 years. (Source: Biology of Blood and Ma...
Source: Biology of Blood and Marrow Transplantation - March 14, 2019 Category: Hematology Authors: Leslie Lehmann Source Type: research

Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with myelodysplastic syndromes (MDS) and acute myelogenous leukemia derived from MDS (sAML) [1,2]. However, there is controversy among experts if and how patients with MDS should receive cytoreductive “debulking” chemotherapy (CTX) before transplant. MDS patients without elevated bone marrow (BM) blast counts usually proceed to transplant without cytoreduction, whereas patients with MDS and excess blasts and those with sAML often receive cytoreductive treatment to achieve remission before tra n...
Source: Biology of Blood and Marrow Transplantation - March 14, 2019 Category: Hematology Authors: Thomas Schroeder, Nadija Wegener, Michael Lauseker, Christina Rautenberg, Kathrin Nachtkamp, Esther Schuler, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Guido Kobbe Source Type: research

Protecting the selfless:towards more comprehensive care for pediatric related stem cell donors
None (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 14, 2019 Category: Hematology Authors: Leslie Lehmann Tags: Title page Source Type: research

Comparison between upfront transplantation and different pre-transplant cytoreductive treatment approaches in patients with high-risk MDS and secondary AML
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative treatment option for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia derived from MDS (sAML) [1,2]. However, there is controversy among experts if and how patients with MDS should receive cytoreductive “debulking” chemotherapy before transplant. MDS patients without elevated bone marrow blast counts usually proceed to transplant without cytoreduction, whereas patients with MDS and excess blasts and those with sAML often receive cytoreductive treatment in order to achieve remission before trans plant...
Source: Biology of Blood and Marrow Transplantation - March 14, 2019 Category: Hematology Authors: Thomas Schroeder, Nadija Wegener, Michael Lauseker, Christina Rautenberg, Kathrin Nachtkamp, Esther Schuler, Mustafa Kondakci, Rainer Haas, Ulrich Germing, Guido Kobbe Source Type: research

A tale of two eras: the story of autologous stem cell transplantation with and without thiotepa for primary central nervous system lymphoma
Primary central nervous system lymphoma (PCNSL) is an aggressive and rare form of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, eyes, or cerebral spinal fluid (CSF)1 with highest incidence in patients over 65.2 Poor performance status at diagnosis often impede enrollment in clinical trials. Thus, therapeutic recommendations are based on a few randomized trials, single arm phase 2 trials and retrospective studies. There is no uniform consensus on the optimal treatment strategy for PCNSL patients. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 14, 2019 Category: Hematology Authors: Bei Hu Source Type: research

Comparison of Graft Acquisition and Early Direct Charges of Haploidentical Related Donor Transplantation versus Umbilical Cord Blood Transplantation
Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for advanced or high-risk hematologic malignancies [1]. With shrinking family size and a limited donor pool for ethnic minorities, the availability of an HLA-matched sibling or unrelated donors can be a challenge [2]. In addition, because an unrelated donor search can take up to 4months [3], many high-risk patients can relapse or succumb to their disease while awaiting identification of a suitably matched donor [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 13, 2019 Category: Hematology Authors: Abraham S. Kanate, Aniko Szabo, Renju V. Raj, Kathryn Bower, Rachel Grulke, Nilay Shah, Kelly G. Ross, Aaron Cumpston, Michael Craig, Marcelo C. Pasquini, Nirav Shah, Parameswaran Hari, Mehdi Hamadani, Saurabh Chhabra Source Type: research

Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions
Allogeneic hematopoietic stem cell transplantation (HSCT) has become the standard of care for many high-risk hematologic malignancies. However, a high relapse rate, first indicated by molecular relapse, remains the leading cause of treatment failure. Cell-based immunotherapy offers promise for eradicating molecular disease and preventing overt relapse following allogeneic HSCT, especially when the leukemia burden is low. Donor immune cell populations can become activated on recognition of specific major histocompatibility complex antigens or minor histocompatibility antigens on host cells and thus can contain leukemia-reac...
Source: Biology of Blood and Marrow Transplantation - March 13, 2019 Category: Hematology Authors: Michael Merker, Emilia Salzmann-Manrique, Verena Katzki, Sabine Huenecke, Melanie Bremm, Shahrzad Bakhtiar, Andre Willasch, Andrea Jarisch, Jan Soerensen, Ansgar Schulz, Roland Meisel, Gesine Bug, Halvard Bonig, Thomas Klingebiel, Peter Bader, Eva Retting Source Type: research

Clearance of hematological malignancies by allogeneic cytokine-induced killer cell or donor lymphocyte infusions
Allogeneic hematopoietic stem cell transplantation (HSCT) has become the standard of care for many high-risk hematological malignancies. However, a high relapse rate, first indicated by molecular relapse, remains the leading cause of treatment failure. Cell-based immunotherapy offers promise for the eradication of molecular disease and prevention of overt relapse following allogeneic HSCT, especially when the leukemia burden is low. Thus, donor immune cell populations can become activated on recognition of specific major histocompatibility complex (MHC) or minor histocompatibility antigens (mHAgs) on host cells and can the...
Source: Biology of Blood and Marrow Transplantation - March 13, 2019 Category: Hematology Authors: Michael Merker, Emilia Salzmann-Manrique, Verena Katzki, Sabine Huenecke, Melanie Bremm, Shahrzad Bakhtiar, Andre Willasch, Andrea Jarisch, Jan Soerensen, Ansgar Schulz, Roland Meisel, Gesine Bug, Halvard Bonig, Thomas Klingebiel, Peter Bader, Eva Retting Source Type: research